Takeda Pharmaceutical Company (4502) 43rd Annual J.P. Morgan Healthcare Conference summary

Strategic focus and R&D investment

• Shifted from generics and OTC to an R&D-driven, innovation-focused model, emphasizing late-stage pipeline development.

• Increased R&D investment to about $5 billion annually, with a focus on six late-stage assets targeting significant unmet needs.

• Pipeline expected to generate peak revenues of $10–20 billion, offsetting future biosimilar threats.

• All six late-stage assets are planned for launch before 2030, with the top three within the next three years.

• Ongoing targeted business development and in-licensing to supplement organic growth.

Pipeline highlights and product differentiation

• TAK-861 (orexin agonist) for narcolepsy type 1 shows near-normalization of symptoms and high efficacy, with digital companion and AI-based diagnostic tools in development.

• Zasocitinib (TYK2 inhibitor) for psoriasis and future IBD indications offers higher selectivity and efficacy, aiming to expand the oral treatment segment.

• Rusfertide for polycythemia vera demonstrates strong hematocrit control and potential to transform treatment standards.

• Mezagitamab (CD38 antibody) for IgAN and ITP offers sustained efficacy with potential dosing holidays and a differentiated safety profile.

• Fazirsiran (siRNA) for AATD targets protein accumulation in the liver, aiming for early diagnosis and intervention.

• Elritercept, in-licensed for low-risk MDS, is effective in both RS-positive and RS-negative patients, expanding treatment options.

Market strategy and competitive positioning

• TAK-861 aims for first-to-market advantage with high efficacy and patient normalization, reducing likelihood of treatment switching.

• Zasocitinib expected to outperform current oral competitors and grow the oral segment in psoriasis and IBD.

• Mezagitamab positioned for safety and convenience, with potential for significant dosing holidays and minimal impact on vaccine response.

• Acknowledges competitive landscape but confident in product differentiation and market entry timing.